
Boston Scientific (BSX) Stock Forecast & Price Target
Boston Scientific (BSX) Analyst Ratings
Bulls say
Boston Scientific demonstrated strong financial performance, highlighted by a gross margin of 70.7%, which exceeded consensus estimates and was buoyed by an improved product mix despite the impact of tariffs. The company's urology, neuromodulation, interventional cardiology, and vascular therapies segments showcased consistent growth, with respective sales increases of 3.2%, 9.9%, and 8.3% in the latest quarter, indicating robust demand for its innovative medical devices. Additionally, potential upside drivers such as accelerated growth in electrophysiology, contributions from recent acquisitions, and further margin expansion suggest a favorable outlook for future revenue streams.
Bears say
Boston Scientific's stock outlook is negatively impacted by a decline in operating margin, which decreased by 10 basis points year-over-year due to rising research and development expenses that overshadowed slight gross margin growth. Organic growth slowed to 12.7% in the fourth quarter of 2025, down from 15.3% in the previous quarter, primarily due to heightened competition and reduced adoption rates for the FARAPULSE device within the atrial fibrillation market. Additionally, the company faces a bear case scenario where sustained revenue growth is projected to remain below 10% amid potential share losses in critical markets, further contributing to an overall contraction in operating margins.
This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.
Boston Scientific (BSX) Analyst Forecast & Price Prediction
Start investing in Boston Scientific (BSX)
Order type
Buy in
Order amount
Est. shares
0 shares